1. Home
  2. BCYC vs ETD Comparison

BCYC vs ETD Comparison

Compare BCYC & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCYC
  • ETD
  • Stock Information
  • Founded
  • BCYC 2009
  • ETD 1932
  • Country
  • BCYC United Kingdom
  • ETD United States
  • Employees
  • BCYC N/A
  • ETD N/A
  • Industry
  • BCYC Biotechnology: Pharmaceutical Preparations
  • ETD Home Furnishings
  • Sector
  • BCYC Health Care
  • ETD Consumer Discretionary
  • Exchange
  • BCYC Nasdaq
  • ETD Nasdaq
  • Market Cap
  • BCYC 587.5M
  • ETD 709.8M
  • IPO Year
  • BCYC 2019
  • ETD 1993
  • Fundamental
  • Price
  • BCYC $7.85
  • ETD $27.89
  • Analyst Decision
  • BCYC Buy
  • ETD Hold
  • Analyst Count
  • BCYC 8
  • ETD 2
  • Target Price
  • BCYC $29.14
  • ETD $32.00
  • AVG Volume (30 Days)
  • BCYC 326.1K
  • ETD 288.6K
  • Earning Date
  • BCYC 05-01-2025
  • ETD 04-23-2025
  • Dividend Yield
  • BCYC N/A
  • ETD 5.64%
  • EPS Growth
  • BCYC N/A
  • ETD N/A
  • EPS
  • BCYC N/A
  • ETD 2.39
  • Revenue
  • BCYC $35,275,000.00
  • ETD $626,650,000.00
  • Revenue This Year
  • BCYC N/A
  • ETD N/A
  • Revenue Next Year
  • BCYC $0.27
  • ETD $2.47
  • P/E Ratio
  • BCYC N/A
  • ETD $11.57
  • Revenue Growth
  • BCYC 30.76
  • ETD N/A
  • 52 Week Low
  • BCYC $7.85
  • ETD $26.13
  • 52 Week High
  • BCYC $28.67
  • ETD $35.62
  • Technical
  • Relative Strength Index (RSI)
  • BCYC 26.05
  • ETD 50.13
  • Support Level
  • BCYC $8.60
  • ETD $27.00
  • Resistance Level
  • BCYC $9.69
  • ETD $27.97
  • Average True Range (ATR)
  • BCYC 0.68
  • ETD 0.75
  • MACD
  • BCYC -0.03
  • ETD 0.11
  • Stochastic Oscillator
  • BCYC 0.00
  • ETD 69.37

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

About ETD Ethan Allen Interiors Inc.

Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.

Share on Social Networks: